Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge

• Published in: Oncology letters Vol. 13; no. 6; pp. 4939 - 4946
• Main Authors: Nakamura, Tomomi, Watanabe, Naomi, Sato, Akemi, Komiya, Kazutoshi, Umeguchi, Hitomi, Hosomi, Toshiya, Hirai, Mitsuharu, Sueoka, Eisaburo, Kimura, Shinya, Sueoka-Aragane, Naoko
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.06.2017; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Adenocarcinoma; Automation; Biomarkers; Biopsy; Care and treatment; Clinical trials; Deoxyribonucleic acid; Development and progression; DNA; Epidermal growth factor; Genetic aspects; Growth factors; Health aspects; Lung cancer; Mutation; Oncology; Patients; Plasma; Population; Response rates; Japan; lung cancer; EGFR-TKI re-challenge; T790M; monitoring system; plasma DNA; HGF
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2017.6085

Re-challenge with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) has been suggested to potentially improve survival in certain populations of patients with advanced lung cancer, but predictive markers for the success of EGFR-TKI re-challenge have not been identified. The present study analyzed 16 re-challenges with EGFR-TKI undertaken in 12 patients with lung adenocarcinoma by investigating T790M and hepatocyte growth factor (HGF) in plasma coupled with clinical characteristics. mutations in plasma DNA were detected using the wild inhibiting PCR and quenched probe system for exon 19 deletions, and T790M and L858R were detected using the mutation-biased PCR and quenched probe system. HGF levels in the plasma were measured by enzyme-linked immunosorbent assay, and the ratio of HGF levels prior to re-challenge to those prior to the previous EGFR-TKI treatment was calculated. Two re-challenges demonstrated partial response, six remained as stable disease and eight had progressive disease (PD). A total of 4 of the 5 patients with a history of T790M positivity based on plasma DNA levels had PD. A total of 7 of the 8 patients who had ≥1.5-fold elevation of HGF prior to re-challenge with EGFR-TKI suffered PD. Elevation of the HGF ratio to ≥1.5 was significantly associated with poor response to EGFR-TKI re-challenge. Having no history of T790M and an HGF ratio <1.5 was significantly associated with a positive response to EGFR-TKI re-challenge. A combination of T790M detection and HGF quantification using plasma is a potentially useful assay system for predicting the effect of EGFR-TKI re-challenge. Future prospective studies are required to confirm the predictive validity of these markers.